User I R, Ekinci S, Kale G, Akyüz C, Büyükpamukçu M, Karnak I, Çiftçi A Ö, Tanyel F C, Şenocak M E
Department of Pediatric Surgery, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Department of Pediatric Surgery, Hacettepe University Faculty of Medicine, Ankara, Turkey.
J Pediatr Urol. 2015 Jun;11(3):118.e1-6. doi: 10.1016/j.jpurol.2014.11.012. Epub 2015 Jan 30.
Outcomes of Wilms tumor improved in last 50 years and excellent survival rates can be achieved especially in case of non-metastatic disease and favorable histology. Nevertheless, bilateral cases still stand as a therapeutic challenge. Prognosis of bilateral Wilms tumor (BWT) is not as good as the unilateral tumors of similar stage and histology in terms of survival and renal function.
Management of BWT is constantly evolving and still stands as a therapeutic challenge. This study is designed to review and share our experiences on this topic from a surgical standpoint.
The records of patients treated in our clinic between 1980 and 2013 according to Turkish Pediatric Group of Oncology protocol were analyzed retrospectively and clinical data, surgical details, pathology results, long term outcomes were analyzed.
Thirteen girls and 7 boys with a mean age of 2,5 years were treated. There were 2 patients with Wilms tumor-Aniridia-Growth Retardation complex and one with isolated hemihypertrophy. Metastasis were detected in lungs of 4 patients; liver of 2 and in the cranium of one. All patients except one with the presumptive diagnosis of unilateral Wilms tumor were given preoperative chemotherapy. To sum up; 19 nephroureterectomies, 8 partial nephrectomies and 13 enucleations were performed to 36 kidneys without any major early or late postoperative complications. Pathologic results revealed positive surgical margins in 2 lesions with enucleation and in 2 with partial nephrectomies and anaplasia in 4 patients. Two patients were not operated due to parental disapproval. Two patients had the need of dialysis; one was anephric and the others' renal functions recovered over a year. Seven patients received radiotherapy for pulmonary metastasis, positive surgical margins or local recurrences. Overall, 13 patients survived and 7 died due to metastasis, recurrences, and complication of dialysis and refusal of surgical treatment. Survival among all patients was 65% and 72.2% among operated ones. Of the 7 patients with the partial nephrectomy, 2 died and 5 survived. Among enucleation group, 8 out of 10 survived and 2 died. Survival was slightly higher among enucleation group (80% vs 71.4%). Median time of follow-up for survivors of disease is 5.8 years (min: 6 months and max: 14 years).
Outcomes of BWT management have changed dramatically during the last few decades from only survival, to a long life expectancy without the need of renal replacement therapy owing to improvements in treatment options. We argue that positive surgical margins do not necessarily lead to local recurrence. For this reason it may be wiser to favor on more nephron sparing surgery than to achieve negative surgical margins. Adjuvant chemotherapy and radiotherapy may be adequate to prevent local recurrence. Also, survival did not differ significantly between different ways of nephron sparing surgeries, so it may be wiser to choose enucleation over partial nephrectomy which preserves more nephrons. Nephron-sparing surgery should have utmost importance despite the risk of positive margins. On the other hand, there is not enough data to interpret if positive surgical margins have role on distant metastases or not. Presence of metastasis and recurrence seems to be an important determinant of prognosis given the fact that none of the survivors had any metastasis or recurrence.
Nephron preservation should be the aim while taking positive surgical margin risk on nephron sparing surgery side relying on postoperative chemotherapy and carefully planned radiotherapy to avoid recurrence. However, there is significant diversity on the management BWT in different centers and a certain validated guideline or protocol to provide the optimal treatment is still lacking.
在过去50年里,肾母细胞瘤的治疗效果有所改善,尤其是在非转移性疾病和组织学类型良好的情况下,可实现优异的生存率。然而,双侧肾母细胞瘤病例仍然是一个治疗挑战。就生存率和肾功能而言,双侧肾母细胞瘤(BWT)的预后不如相同分期和组织学类型的单侧肿瘤。
BWT的治疗方法不断发展,仍然是一个治疗挑战。本研究旨在从外科角度回顾并分享我们在这个主题上的经验。
回顾性分析1980年至2013年期间在我们诊所按照土耳其儿科肿瘤学组方案治疗的患者记录,并分析临床数据、手术细节、病理结果和长期预后。
共治疗了13名女孩和7名男孩,平均年龄2.5岁。有2例患者患有肾母细胞瘤-无虹膜-生长发育迟缓综合征,1例患有孤立性半身肥大。在4例患者的肺部、2例患者的肝脏和1例患者的颅骨中检测到转移。除1例初步诊断为单侧肾母细胞瘤的患者外,所有患者均接受了术前化疗。总之,对36个肾脏进行了19次肾输尿管切除术、8次部分肾切除术和13次肿瘤剜除术,术后无任何重大早期或晚期并发症。病理结果显示,2例肿瘤剜除术和2例部分肾切除术的手术切缘阳性,4例患者存在间变。2例患者因家长不同意未进行手术。2例患者需要透析;1例无肾,另1例肾功能在1年内恢复。7例患者因肺转移、手术切缘阳性或局部复发接受放疗。总体而言,13例患者存活,7例因转移、复发、透析并发症和拒绝手术治疗死亡。所有患者的生存率为65%,手术患者的生存率为72.2%。在7例接受部分肾切除术的患者中,2例死亡,5例存活。在肿瘤剜除术组中,10例中有8例存活,2例死亡。肿瘤剜除术组的生存率略高(80%对71.4%)。疾病幸存者的中位随访时间为5.8年(最短:6个月,最长:14年)。
在过去几十年中,BWT的治疗结果发生了巨大变化,从仅关注生存,到由于治疗方案的改进,有望实现无需肾脏替代治疗的长期预期寿命。我们认为手术切缘阳性不一定会导致局部复发。因此,相比实现阴性手术切缘,更倾向于选择保留肾单位手术可能更为明智。辅助化疗和放疗可能足以预防局部复发。此外,不同的保留肾单位手术方式之间生存率无显著差异,因此选择肿瘤剜除术而非保留更多肾单位的部分肾切除术可能更为明智。尽管存在手术切缘阳性的风险,但保留肾单位手术仍应至关重要。另一方面,没有足够的数据来解释手术切缘阳性是否对远处转移有影响。鉴于幸存者均无任何转移或复发,转移和复发的存在似乎是预后的重要决定因素。
在保留肾单位手术时应承担手术切缘阳性的风险,同时以保留肾单位为目标,依靠术后化疗和精心规划的放疗来避免复发。然而,不同中心在BWT的治疗上存在显著差异,仍然缺乏能够提供最佳治疗方案的经过验证的指南或方案。